Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.16M$2.16Mderived−50.0% vs Q4 2020 Net Income-$3.66M-$3.66MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$193,000N/M Operating Incomederived-$2,815,000N/M Operating Cash Flowderived-$1,476,000N/M Free Cash Flowderived-$1,481,000N/M Margins · derivedGross margin-8.9%−47.3 pt vs Q4 2020
Operating margin-130.5%−55.7 pt vs Q4 2020
Net margin-169.7%−129.4 pt vs Q4 2020
ended Mar 31, 2021 · filed Jul 14, 2021 · 105 d after period end